Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.
ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.
ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q4 2025 net revenue of $247.1M (+29.6% YoY) and full‑year revenue of $883.4M (+43.8% YoY). Cortrophin Gel drove Rare Disease growth with Q4 revenue of $111.4M (+87.6%) and full‑year $347.8M (+75.6%).
The company posted Q4 GAAP EPS $1.18 and adjusted non‑GAAP diluted EPS $2.33, record adjusted EBITDA of $65.4M Q4 and $229.8M full year, and reaffirmed 2026 guidance targeting >$1B revenue and adjusted EBITDA $275M–$290M.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani and executive leaders will present at three investor conferences in March 2026: Raymond James (Mar 3), Leerink Partners Global Healthcare (Mar 10), and Barclays Global Healthcare (Mar 11).
Live and archived webcasts will be available via the company’s Investors section, with replays accessible for 90 days.
ANI Pharmaceuticals (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. A conference call and live webcast at 8:00 a.m. ET will discuss the results, with replay available for 12 months.
Executives on the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. The webcast and replay will be available under Investors > Events and Presentations at www.anipharmaceuticals.com. Dial-in details include toll-free U.S. access and Conference ID 5230834.
ANI Pharmaceuticals (Nasdaq: ANIP) reported preliminary, unaudited full year 2025 results and provided full year 2026 guidance on Jan 12, 2026. ANI expects 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above prior guidance ranges of $854M–$873M, $221M–$228M, and $7.37–$7.64, respectively. Cortrophin Gel net revenues were approximately $347.8M in 2025 (up 76% YoY) and $111.4M in Q4 2025 (up 88% YoY). 2026 guidance: $1,055M–$1,115M total net revenues; Cortrophin Gel $540M–$575M; adjusted non-GAAP EBITDA $275M–$290M; adjusted non-GAAP diluted EPS $8.83–$9.34. ANI expects Rare Disease to be ~60% of 2026 revenue, plans a ~90-person Rare Disease expansion, and will present at the J.P. Morgan Healthcare Conference on Jan 13, 2026.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET.
The presentation will be available via a live webcast and an archived replay on the company website under Investors > Events and Presentations. The replay will be accessible for 30 days.
ANI Pharmaceuticals (Nasdaq: ANIP) announced on December 2, 2025 the formation of the FutureVision Advisory Council to guide its ophthalmology and retina franchise within the Rare Disease business.
The council comprises seven retina and three uveitis specialists, co‑led by Arshad M. Khanani, MD (Principal Retina Advisor and Chair) and Peter Y. Chang, MD (Principal Uveitis Advisor and Chair). The council will advise on strategic advancement of current products, including ILUVIEN and Cortrophin Gel, and on development priorities to support patient care.
ANI Pharmaceuticals (Nasdaq: ANIP) announced a Board leadership change on Dec 1, 2025. Patrick D. Walsh has stepped down as Chairman and will retire from the board after completing his current term at the Company’s 2026 Annual Meeting of Stockholders. The Board unanimously elected Thomas J. Haughey, a director since May 2018, as the next Chairman. Mr. Haughey will relinquish the role of Chair of the Audit and Finance Committee and remain on that committee and the Nominating and Corporate Governance Committee.
Jeanne Thoma, a director since August 2020, will become Chair of the Audit and Finance Committee. Management framed the transition as orderly and focused on continuity while the company expands its Rare Disease business.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that Chief Executive Officer Nikhil Lalwani will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET. The event will be available live and via archived webcast on the company website under Investors > Events and Presentations. The replay will be accessible for 90 days following the live presentation.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.
The live webcast and an archived replay will be available via the company’s investor website under Events and Presentations and will remain accessible for 90 days.
ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q3 2025 net revenues of $227.8M, a 53.6% year‑over‑year increase, driven by Purified Cortrophin Gel $101.9M (up 93.8%). The company reported record adjusted non‑GAAP EBITDA of $59.6M and adjusted non‑GAAP diluted EPS of $2.04, with GAAP diluted EPS of $1.13.
ANI raised full‑year 2025 guidance to $854M–$873M total net revenue, adjusted non‑GAAP EBITDA of $221M–$228M, and adjusted non‑GAAP diluted EPS of $7.37–$7.64. Rare Disease is expected to represent about 50% of 2025 net revenues, including revised Cortrophin Gel guidance of $347M–$352M (≈75%–78% growth).